The complex tasks of making a confident diagnosis of a specific form of interstitial lung
disease (ILD) and formulating a patient-centered, personalized management plan in an …

Background: Dyspnea is a common, distressing symptom of cardiopulmonary and
neuromuscular diseases. Since the ATS published a consensus statement on dyspnea in …

Abstract Context The Dyspnoea-12 (D-12) and Multidimensional Dyspnea Profile (MDP)
were specifically developed for assessment of multiple sensations of breathlessness …

Background: In the past two decades, many advances have been made to our
understanding of interstitial lung disease (ILD) and the way we approach its treatment …

Background Those affected by advanced fibrotic interstitial lung diseases (ILDs) have
considerable unmet symptom and psychological needs. Case conferencing has been …

Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack
of consensus on appropriate outcome measures for reliably assessing treatment response …

Background Most measures of dyspnea assess a single aspect (intensity or distress) of the
symptom. We developed the Multidimensional Dyspnea Profile (MDP) to measure qualities …

Objectives To describe comorbid conditions in patients with rheumatoid arthritis–associated
interstitial lung disease (RA-ILD) and to analyze factors associated with multimorbidity …

Background. Dyspnea is a prominent symptom in asthma. The Dyspnea-12 (D-12), an
instrument that quantifies breathlessness using 12 descriptors that tap the physical and …

Fatigue is one of the most burdensome symptoms in interstitial lung disease (ILD) and can
have a major impact on quality of life, social interactions, and work capacity. The cause of …